Key result
High-throughput screening identifies ~50 novel small-molecule antagonists against the Kv1.3 potassium channel.
Why the study?
A functional cell-based assay was needed to identify novel small-molecule antagonists against the Kv1.3 potassium ion channel with potency and selectivity.
A high-throughput fluorescent cell-based assay successfully identified novel small-molecule antagonists with potency and selectivity against the Kv1.3 potassium ion channel.
Requires validation before clinical use; extends chemical matter for Kv1.3 antagonist discovery.
A functional cell-based assay was developed using a generic proprietary assay protocol, based on a membrane-potential sensitive dye, for the identification of small-molecule antagonists against the Kv1.3 potassium ion channel. A high-throughput screen (HTS) was subsequently performed with 20,000 compounds from the Evotec library, preselected using known small molecule antagonists for both sodium and potassium ion channels. Following data analysis, the hit rate was measured at 1.72%, and subsequent dose-response analysis of selected hits showed a high hit confirmation rate yielding approximately 50 compounds with an apparent IC50 value lower than 10 microM. Subsequent electrophysiological characterization of selected hits confirmed the initial activity and potency of the identified hits on the Kv1.3 target and also selectivity toward Kv1.3 through measurements on HERG as well as Kv1.3-expressing cell lines. Follow-up structure-activity relationship analysis revealed a variety of different clusters distributed throughout the library as well as several singlicates. In comparison to known Kv1.3 blockers, new chemical entities and scaffolds showing potency and selectivity against the Kv1.3 ion channel were detected. In addition, a screening strategy for ion channel drug discovery HTS, medicinal chemistry, and electrophysiology is presented.
No takes yet. Share an insight, caveat, or question.
Slack et al. (2006) studied Kv1.3 potassium ion channel drug discovery. High-throughput screening of small-molecule compounds was evaluated on Hit rate. A high-throughput screen of 20,000 compounds yielded a 1.72% hit rate, identifying approximately 50 novel small-molecule antagonists with an IC50 <10 microM against the Kv1.3 potassium ion channel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: